Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.0362043795620437 0.0364963503649635
Stock impact report

NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNK? Cell Therapy with Superagonist IL-15 Cytokine Th...

NANTKWEST (NK) 
Last nantkwest earnings: 3/25 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nantkwest.com
Company Research Source: Business Wire
Study Tests Elimination Of Chemotherapy And Expands Upon Previous Combination Study Of NK Cell Therapy With N-803 Showing Promising Clinically Meaningful Responses In Merkel Cell Carcinoma Patients CULVER CITY, Calif.--(BUSINESS WIRE)-- NantKwest Inc. (Nasdaq:NK), a leading, clinical-stage, natural killer cell based therapeutics company, today announced the launch of a novel triple combination, phase II clinical trial in Merkel cell carcinoma (MCC). NantKwest’s phase II immunotherapy trial builds upon the company’s earlier phase II single-combination study using its proprietary, off-the-shelf aNKTM natural killer cell therapy and IL-15/Fc superagonist (N-803), which produced an objective responses in 3 of 7 patients. In this new clinical trial, patients will be dosed with: (i) the novel chemotherapy-free combination of our haNK cell therapy, which are aNK cells that are genetica Show less Read more
Impact Snapshot
Event Time:
NK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NK alerts
Opt-in for
NK alerts

from News Quantified
Opt-in for
NK alerts

from News Quantified